User:Mr. Ibrahem/Teplizumab

Teplizumab, sold under the brand name Tzield, is a medication used in early type 1 diabetes (antibodies present to islet cells, abnormal blood sugar levels, but no symptoms) to decrease progression symptomatic disease. It is used in those who are at least 8 years old. It is given by gradual injection into a vein.

Common side effects include headache, rash, and low white blood cells. Other side effects may include cytokine release syndrome, infection, and allergic reactions. Use in pregnancy may harm the baby. It is a monoclonal antibody that blocks CD3 found on T lymphocytes. It is believed that this decreases their attacking pancreatic beta cells.

Teplizumab was approved for medical use in the United States in 2022. As of 2022 it is not approved in Europe or the United Kingdom. The two week course of treatment costs about 200,000 USD in the United States as of 2022.